News

Filter

Current filters:

LicensingImmunologicals

1 to 9 of 61 results

AstraZeneca inks deal with Orca for autoimmune disease drugs

AstraZeneca inks deal with Orca for autoimmune disease drugs

25-02-2015

Anglo-Swedish pharma major AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company,…

AstraZenecaBiotechnologyImmunologicalsInflammatory diseasesLicensingOrca PharmaceuticalsRespiratory and PulmonaryUK

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

EpiVax links with Novozymes Biopharma to advance autoimmune diseases treatment

23-12-2014

Danish drugmaker Novozymes’ Veltis albumin-based half-life extension platform will help move Tregitope…

BiotechnologyImmunologicalsLicensingNovozymesResearchTregitopeVeltis

Tiziana licenses anti-inflammatory foralumab from Novimmune

Tiziana licenses anti-inflammatory foralumab from Novimmune

22-12-2014

Oncology and immunology specialist Tiziana and antibody-based drug manufacturer Novimmune have entered…

BiotechnologyImmunologicalsLicensingNovImmuneTiziana

GlaxoSmithKline drops option for Dynavax’ DV1179

28-11-2014

USA-based Dynavax Technologies (Nasdaq: DVAX) today announced that it has regained full rights to DV1179,…

DV1179Dynavax TechnologiesGlaxoSmithKlineImmunologicalsLicensingPharmaceuticalResearch

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

26-06-2014

Japanese firm Teijin has entered into an agreement with the UK subsidiary of privately-owned Italian…

EZN-2279ImmunologicalsJapanLicensingPharmaceuticalSigma-TauTeijin

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

1 to 9 of 61 results

COMPANY SPOTLIGHT

Menarini

Back to top